An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders
An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders
We aimed to identify diagnosis-specific/transdiagnostic/transoutcome multivariable candidate predictors (MCPs) of key outcomes in mental disorders. We conducted an umbrella review (protocol link), searching MEDLINE/Embase (19/07/2022), including systematic reviews of studies reporting on MCPs of response, remission, recovery, or relapse, in DSM/ICD-defined mental disorders. From published predictors, we filtered MCPs, validating MCP criteria. AMSTAR2/PROBAST measured quality/risk of bias of systematic reviews/individual studies. We included 117 systematic reviews, 403 studies, 299,888 individuals with mental disorders, testing 796 prediction models. Only 4.3%/1.2% of the systematic reviews/individual studies were at low risk of bias. The most frequently targeted outcome was remission (36.9%), the least frequent was recovery (2.5%). Studies mainly focused on depressive (39.4%), substance-use (17.9%), and schizophrenia-spectrum (11.9%) disorders. We identified numerous MCPs within disorders for response, remission and relapse, but none for recovery. Transdiagnostic MCPs of remission included lower disease-specific symptoms (disorders = 5), female sex/higher education (disorders = 3), and quality of life/functioning (disorders = 2). Transdiagnostic MCPs of relapse included higher disease-specific symptoms (disorders = 5), higher depressive symptoms (disorders = 3), and younger age/higher anxiety symptoms/global illness severity/ number of previous episodes/negative life events (disorders = 2). Finally, positive trans-outcome MCPs for depression included less negative life events/depressive symptoms (response, remission, less relapse), female sex (response, remission) and better functioning (response, less relapse); for schizophrenia, less positive symptoms/higher depressive symptoms (remission, less relapse); for substance use disorder, marital status/higher education (remission, less relapse). Male sex, younger age, more clinical symptoms and comorbid mental/physical symptoms/disorders were poor prognostic factors, while positive factors included social contacts and employment, absent negative life events, higher education, early access/intervention, lower disease-specific and comorbid mental and physical symptoms/conditions, across mental disorders. Current data limitations include high risk of bias of studies and extraction of single predictors from multivariable models. Identified MCPs can inform future development, validation or refinement of prediction models of key outcomes in mental disorders.
3671-3687
Solmi, Marco
2022a2e4-774d-4811-b1db-b6dbfedbd10d
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Vita, Giovanni
a9caadad-bccc-4774-91c1-2f84f3e303ff
De Prisco, Michele
d463612d-12e8-4344-9c52-86ef341f4d2f
Radua, Joaquim
7443399e-6de8-48ac-a6cb-3b8663151462
Dragioti, Elena
737161f7-ec35-4d20-80eb-5f382c0aa9b6
Köhler-forsberg, Ole
0e3198bb-cf2a-4a91-ab26-721cb666906a
Madsen, Nanna M.
05d625eb-45a4-429c-9477-c1f9ed805f7c
Rohde, Christopher
7a21f173-8d11-4c42-ad13-34567ec23b73
Eudave, Luis
f736791a-8a5f-4d3f-b273-9354922d160c
Aymerich, Claudia
c8cc318c-4c05-4d39-9d68-d881fa90710d
Pedruzo, Borja
072647ec-e009-4dfb-9d71-c673e8eee033
Rodriguez, Victoria
0b214cf0-d5a4-4ac7-a17a-4e7668d185c3
Rosson, Stella
6d0d0f05-a0e2-46cf-9a68-37f699ede363
Sabé, Michel
d14be66a-e6c6-478a-b956-03e79a7f462e
Hojlund, Mikkel
45cd17b3-84af-40be-8f6d-ef641a17ca47
Catalan, Ana
50bd5b40-15a0-48cc-8f9a-f3661ae133b5
De Luca, Beatrice
afe5bdb5-4f49-4476-8d01-1ebf6bc9dd27
Fornaro, Michele
b817f7f5-0787-4906-91ab-a71c87053e34
Ostuzzi, Giovanni
b3a9830f-177c-41a3-831f-959019e39afb
Barbui, Corrado
8c2c60a7-0929-4317-8684-73ec57f49385
Salazar-de-Pablo, Gonzalo
69c91c10-f1ec-4a17-9e08-e6555d769496
Fusar-poli, Paolo
dfb80ff8-8a29-4a23-899d-e7311b855433
Correll, Christoph U.
64860443-88af-4c24-b83b-1e4a6572c8dc
13 November 2023
Solmi, Marco
2022a2e4-774d-4811-b1db-b6dbfedbd10d
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Vita, Giovanni
a9caadad-bccc-4774-91c1-2f84f3e303ff
De Prisco, Michele
d463612d-12e8-4344-9c52-86ef341f4d2f
Radua, Joaquim
7443399e-6de8-48ac-a6cb-3b8663151462
Dragioti, Elena
737161f7-ec35-4d20-80eb-5f382c0aa9b6
Köhler-forsberg, Ole
0e3198bb-cf2a-4a91-ab26-721cb666906a
Madsen, Nanna M.
05d625eb-45a4-429c-9477-c1f9ed805f7c
Rohde, Christopher
7a21f173-8d11-4c42-ad13-34567ec23b73
Eudave, Luis
f736791a-8a5f-4d3f-b273-9354922d160c
Aymerich, Claudia
c8cc318c-4c05-4d39-9d68-d881fa90710d
Pedruzo, Borja
072647ec-e009-4dfb-9d71-c673e8eee033
Rodriguez, Victoria
0b214cf0-d5a4-4ac7-a17a-4e7668d185c3
Rosson, Stella
6d0d0f05-a0e2-46cf-9a68-37f699ede363
Sabé, Michel
d14be66a-e6c6-478a-b956-03e79a7f462e
Hojlund, Mikkel
45cd17b3-84af-40be-8f6d-ef641a17ca47
Catalan, Ana
50bd5b40-15a0-48cc-8f9a-f3661ae133b5
De Luca, Beatrice
afe5bdb5-4f49-4476-8d01-1ebf6bc9dd27
Fornaro, Michele
b817f7f5-0787-4906-91ab-a71c87053e34
Ostuzzi, Giovanni
b3a9830f-177c-41a3-831f-959019e39afb
Barbui, Corrado
8c2c60a7-0929-4317-8684-73ec57f49385
Salazar-de-Pablo, Gonzalo
69c91c10-f1ec-4a17-9e08-e6555d769496
Fusar-poli, Paolo
dfb80ff8-8a29-4a23-899d-e7311b855433
Correll, Christoph U.
64860443-88af-4c24-b83b-1e4a6572c8dc
Solmi, Marco, Cortese, Samuele, Vita, Giovanni, De Prisco, Michele, Radua, Joaquim, Dragioti, Elena, Köhler-forsberg, Ole, Madsen, Nanna M., Rohde, Christopher, Eudave, Luis, Aymerich, Claudia, Pedruzo, Borja, Rodriguez, Victoria, Rosson, Stella, Sabé, Michel, Hojlund, Mikkel, Catalan, Ana, De Luca, Beatrice, Fornaro, Michele, Ostuzzi, Giovanni, Barbui, Corrado, Salazar-de-Pablo, Gonzalo, Fusar-poli, Paolo and Correll, Christoph U.
(2023)
An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.
Molecular Psychiatry, 28 (9), .
(doi:10.1038/s41380-023-02298-3).
Abstract
We aimed to identify diagnosis-specific/transdiagnostic/transoutcome multivariable candidate predictors (MCPs) of key outcomes in mental disorders. We conducted an umbrella review (protocol link), searching MEDLINE/Embase (19/07/2022), including systematic reviews of studies reporting on MCPs of response, remission, recovery, or relapse, in DSM/ICD-defined mental disorders. From published predictors, we filtered MCPs, validating MCP criteria. AMSTAR2/PROBAST measured quality/risk of bias of systematic reviews/individual studies. We included 117 systematic reviews, 403 studies, 299,888 individuals with mental disorders, testing 796 prediction models. Only 4.3%/1.2% of the systematic reviews/individual studies were at low risk of bias. The most frequently targeted outcome was remission (36.9%), the least frequent was recovery (2.5%). Studies mainly focused on depressive (39.4%), substance-use (17.9%), and schizophrenia-spectrum (11.9%) disorders. We identified numerous MCPs within disorders for response, remission and relapse, but none for recovery. Transdiagnostic MCPs of remission included lower disease-specific symptoms (disorders = 5), female sex/higher education (disorders = 3), and quality of life/functioning (disorders = 2). Transdiagnostic MCPs of relapse included higher disease-specific symptoms (disorders = 5), higher depressive symptoms (disorders = 3), and younger age/higher anxiety symptoms/global illness severity/ number of previous episodes/negative life events (disorders = 2). Finally, positive trans-outcome MCPs for depression included less negative life events/depressive symptoms (response, remission, less relapse), female sex (response, remission) and better functioning (response, less relapse); for schizophrenia, less positive symptoms/higher depressive symptoms (remission, less relapse); for substance use disorder, marital status/higher education (remission, less relapse). Male sex, younger age, more clinical symptoms and comorbid mental/physical symptoms/disorders were poor prognostic factors, while positive factors included social contacts and employment, absent negative life events, higher education, early access/intervention, lower disease-specific and comorbid mental and physical symptoms/conditions, across mental disorders. Current data limitations include high risk of bias of studies and extraction of single predictors from multivariable models. Identified MCPs can inform future development, validation or refinement of prediction models of key outcomes in mental disorders.
Text
s41380-023-02298-3
- Version of Record
More information
Accepted/In Press date: 6 October 2023
Published date: 13 November 2023
Additional Information:
Funding Information:
CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. CR received the 2020 Lundbeck Foundation Talent Prize. OK-F received honoraria for lectures for Lundbeck Pharma A/S and consultant work for WCG Clinical. MH has been consultant for or has received honoraria from: H. Lundbeck, The Lundbeck Foundation and Otsuka. MS received honoraria/has been a consultant for AbbVie, Angelini, Lundbeck, Otsuka. All other authors declare no conflict of interest.
Funding Information:
CR is supported by a grant from the Lundbeck Foundation (grant number: R358-2020-2342) and grants from the Novo Nordisk Foundation (grant numbers: NNF17SA0031406 and NNF14OC0011633). SC is currently supported by funding from the National Institute for Health and Care Research, NIHR (grants NIHR203684, NIHR203035, NIHR130077, NIHR128472, RP-PG-0618-20003), Solent NHS Trust (Researh Capability Funding, 2022), University of Southampton (Knowledge and Exchange Enterprise Fund 2023, Enterprise Development Fund 2022) and European Research Agency (Horizon: Project 101095568.). Open Access funding enabled and organized by Projekt DEAL.
Publisher Copyright:
© 2023, The Author(s).
Identifiers
Local EPrints ID: 485658
URI: http://eprints.soton.ac.uk/id/eprint/485658
ISSN: 1359-4184
PURE UUID: b9b6f9de-0271-459d-ade4-a32508cd6d6a
Catalogue record
Date deposited: 13 Dec 2023 17:39
Last modified: 18 Mar 2024 03:31
Export record
Altmetrics
Contributors
Author:
Marco Solmi
Author:
Giovanni Vita
Author:
Michele De Prisco
Author:
Joaquim Radua
Author:
Elena Dragioti
Author:
Ole Köhler-forsberg
Author:
Nanna M. Madsen
Author:
Christopher Rohde
Author:
Luis Eudave
Author:
Claudia Aymerich
Author:
Borja Pedruzo
Author:
Victoria Rodriguez
Author:
Stella Rosson
Author:
Michel Sabé
Author:
Mikkel Hojlund
Author:
Ana Catalan
Author:
Beatrice De Luca
Author:
Michele Fornaro
Author:
Giovanni Ostuzzi
Author:
Corrado Barbui
Author:
Gonzalo Salazar-de-Pablo
Author:
Paolo Fusar-poli
Author:
Christoph U. Correll
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics